Peptide therapeutics have many advantages. #Immunotherapy #wvc2022

In June, we join Cancer Research Institute in celebrating 10 years of Cancer Immunotherapy Month! #Immunotherapy has the potential to bring targeted, long-lasting therapies to #cancer patients. Get involved with Cancer Research Institute here: bit.ly/3woVbXj #Immune2Cancer

Future RI governor Helena Foulkes talking about aligning strategy on corporate purpose. She's a cancer survivor and was head of IR when CVS Pharmacy removed tobacco from their stores. 👏🏻 #niri2022

Le gouvernement du #Québec renforce son budget dédié à l'innovation en #sciencesdelavie. Une bonne nouvelle pour le secteur qui traverse actuellement une période difficile. lnkd.in/eBxi5qui

When antigens are delivered the right way to the immune system, it generates a targeted response that leads to clinical benefit with limited adverse events. MVP-S is IMV's first DPX-enabled #cancervaccine and has shown durable clinical benefit in several…lnkd.in/e-3cei8S

Pensez-vous être suffisamment outillé pour gérer une crise lorsqu'elle se présentera ? Peut-on être trop préparé ? (demandez aux pompiers). RDV le 25 avril. lnkd.in/gMJHRZYA

The #biotech industry has always experienced the full throes of the business cycle, and this time is no different. Many of us believe the worst carnage in the #PublicMarkets is now behind us, so hopefully we can start the healthy p…lnkd.in/ex2rjeFb lnkd.in/e7kN_2Aa

Data presented today at the American Association of Cancer Research show that treatment with our lead #CancerVaccine (MVP-S) elicited a robust immune response against #OvarianCancer cells. Experiments demonstrate that T cells are able to migrate into tumo…lnkd.in/ebBKz4VT

Création d’un pôle d’innovation dédié aux #SciencesDeLaVie et de la #SantéDurable sur les installations de Medicago à Québec! When life gives you lemons, make lemonade! #innovation Québec VITAE #VilleDeQuébec lnkd.in/eYQ7hGqT

Jour 2 à EFFERVESCENCE MTL où je suis ravie de représenter l'Agence IMPAKT Scientifik Inc., une entreprise québécoise spécialisée dans la communication scientifique ! Venez me rencontrer pour en savoir plus.! lnkd.in/eyFS7krG

The use of #AI in #oncology is rapidly increasing, and it has the potential to revolutionize #cancer diagnosis, treatment, and research. #DeepLearning models can also help clinicians predict the future development of cancer and som…lnkd.in/exDRDaMs lnkd.in/e2A3-GcQ

Mobilisation locale pour reprendre les installations de Medicago et faire de la Ville de Québec un pôle de recherche biopharmaceutique. #biotech #biopharma lnkd.in/eCzGnr_6

Viens réseauter avec les professionnels de la #Communication et du #Marketing de la #CapitaleNationale ce jeudi soir en terrasse. Notre comité événement a commandé une belle température pour l'occasion ! lnkd.in/e3Tg7kBD

Forget about #DesignThinking. AI requires a different skill, #EmergentThinking: generating ideas for innovation without fully understanding the problem that needs to be solved. #ChatGPT is an unprecedented technology that has pote…lnkd.in/eYPe4NkB lnkd.in/eGhVdjVx

As macroeconomic trends continue to squeeze investment in #biotech companies, #AI-driven companies clearly have a prominent position in the #pharmaceutical industry. We are now starting to see impact in the AI-driven biotech compa…lnkd.in/eNapNUqU lnkd.in/eM92EemC

Single-agent activity and durable #tumor control: #MDNA11 shows tumor control in 37% of patients. #MDNA11 demonstrated partial response in a patient with a highly aggressive tumor type. For more updates, click the link ir.medicenna.com/news-releases/…

In Ph1 trial, Medicenna Therapeutics MDNA11 #monotherapy was well tolerated across all cohorts and has shown promising therapeutic activity in patients who have progressed on multiple prior anti-#cancer therapies including a patient with a particularly aggressive form of #PancreaticCancer.

Last June, our lead asset (MDNA55 or bizaxofusp) was featured on the cover page of #NeuroOncologyJournal. In this Phase 2b study in patients with rec. #glioblastoma, MDNA55 has doubled the mOS compared to SOC. All details in this #publication: ncbi.nlm.nih.gov/pmc/articles/P…

#TBT to our clinical update on the ABILITY study in patients with advanced solid tumors. MDNA11 demonstrated an excellent #SafetyProfile across all cohorts and early signs of response: #PartialResponse in a patient with pancreatic cancer. See more here: bit.ly/46gZFP1

This Monday, we will present the preclinical results of our dual-functioning MDNA223 BiSKIT at the AACR Special Conference in #CancerResearch: Tumor Immunology and #Immunotherapy. Learn about our MDNA BiSKIT program here: bit.ly/468DydM